Clinical trials in Houston, TX

687 recruiting studies have a site in or near Houston, TX, Texas.

Top conditions here

All conditions

Showing 40 of 687 studies

RecruitingPhase 3NCT04047628

Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Dallas, TX · Houston, TX · +21 more sites

RecruitingPhase 3NCT06136650

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

Sponsor: Merck Sharp & Dohme LLC

Austin, TX · Dallas, TX · +60 more sites

RecruitingPhase 3NCT06345729

A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)

Sponsor: Merck Sharp & Dohme LLC

Houston, TX · +14 more sites

RecruitingPhase 3NCT07213674

A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

Sponsor: Amgen

Arlington, TX · Dallas, TX · Houston, TX · +43 more sites

RecruitingPhase 3NCT07654374

A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)

Sponsor: Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics

Austin, TX · Farmers Branch, TX · Houston, TX · +71 more sites

RecruitingPhase 2NCT07752979

Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities

Sponsor: AbbVie

Amarillo, TX · Austin, TX · Bellaire, TX · +56 more sites

RecruitingPhase 3NCT03150693

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

Sponsor: Alliance for Clinical Trials in Oncology

Houston, TX · Lubbock, TX · +453 more sites

RecruitingPhase 3NCT03394365

A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy

Sponsor: Pierre Fabre Medicament

Dallas, TX · Houston, TX · +37 more sites

RecruitingPhase 3NCT04267848

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Sponsor: National Cancer Institute (NCI)

Abilene, TX · Amarillo, TX · Austin, TX · +1147 more sites

RecruitingPhase 2NCT05873192

Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer

Sponsor: M.D. Anderson Cancer Center

Houston, TX

RecruitingPhase 1 / Phase 2NCT06162221

Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

Sponsor: Revolution Medicines, Inc.

Houston, TX · Irving, TX · +27 more sites

RecruitingPhase 2NCT06317662

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

Sponsor: National Cancer Institute (NCI)

Austin, TX · Corpus Christi, TX · Dallas, TX · +112 more sites

RecruitingNot applicableNCT06891755

Bronchoscopic RElease of Air Trapped in Hyperinflated Emphysematous Lung - Study 3

Sponsor: Apreo Health, Inc.

Houston, TX · +17 more sites

RecruitingPhase 3NCT07190209

Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype

Sponsor: Sanofi

Allen, TX · Beaumont, TX · Bellaire, TX · +72 more sites

RecruitingPhase 3NCT07404865

Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease

Sponsor: Vor Biopharma

Allen, TX · Amarillo, TX · +44 more sites

RecruitingPhase 3NCT07525206

A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer

Sponsor: AbbVie

Abilene, TX · Houston, TX · +16 more sites

RecruitingPhase 3NCT07611110

AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)

Sponsor: AstraZeneca

Houston, TX · +27 more sites

RecruitingPhase not listedNCT04302272

STRIVE Post-Market Registry Study

Sponsor: Olympus Corporation of the Americas

Dallas, TX · Houston, TX · +13 more sites

RecruitingPhase 2NCT05554393

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

Sponsor: National Cancer Institute (NCI)

Houston, TX · +173 more sites

RecruitingPhase 3NCT05980949

Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)

Sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Cypress, TX · DeSoto, TX · El Paso, TX · +145 more sites

RecruitingPhase 2NCT06273072

Metformin IN Asthma for Overweight and Obese Individuals (MINA)

Sponsor: Johns Hopkins University

Houston, TX · +1 more sites

RecruitingNot applicableNCT06423430

Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)

Sponsor: Abbott Medical Devices

Austin, TX · Dallas, TX · Houston, TX · +23 more sites

RecruitingPhase 1NCT06465069

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

Sponsor: Eli Lilly and Company

Houston, TX · San Antonio, TX · +21 more sites

RecruitingPhase 3NCT06623422

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

Sponsor: Merck Sharp & Dohme LLC

Dallas, TX · Houston, TX · +51 more sites

RecruitingPhase 1 / Phase 2NCT06810544

Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

Sponsor: Tango Therapeutics, Inc.

Houston, TX · +14 more sites

RecruitingPhase 3NCT06819878

A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

Sponsor: Hoffmann-La Roche

Arlington, TX · El Paso, TX · Georgetown, TX · +92 more sites

RecruitingPhase 1NCT06846606

Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS

Sponsor: Auron Therapeutics, Inc.

Houston, TX · +8 more sites

RecruitingPhase 1 / Phase 2NCT07038343

AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)

Sponsor: Avenzo Therapeutics, Inc.

Dallas, TX · Houston, TX · San Antonio, TX · +16 more sites

RecruitingPhase 1 / Phase 2NCT07061574

A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes

Sponsor: City of Hope Medical Center

Houston, TX · +10 more sites

RecruitingPhase 2NCT07137598

A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)

Sponsor: Hoffmann-La Roche

Colleyville, TX · Houston, TX · Tomball, TX · +15 more sites

RecruitingPhase 3NCT07365995

A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer

Sponsor: BioNTech SE

Austin, TX · Houston, TX · Tyler, TX · +18 more sites

RecruitingPhase 2NCT07620392

An Extension Study to Assess Long-Term Safety and Efficacy of Afimkibart in Participants With Rheumatoid Arthritis

Sponsor: Hoffmann-La Roche

Houston, TX · Tomball, TX · +3 more sites

RecruitingPhase 3NCT07674654

A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine

Sponsor: Kallyope Inc.

Austin, TX · Cypress, TX · +110 more sites

RecruitingPhase 1NCT06120283

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

Sponsor: BeOne Medicines

Houston, TX · Irving, TX · San Antonio, TX · +6 more sites

RecruitingPhase 3NCT06170788

Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

Sponsor: Merck Sharp & Dohme LLC

Houston, TX · +14 more sites

RecruitingPhase 1 / Phase 2NCT06239194

Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

Sponsor: ModeX Therapeutics, An OPKO Health Company

Houston, TX · San Antonio, TX · +4 more sites

RecruitingPhase 3NCT06439082

A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)

Sponsor: Novartis Pharmaceuticals

Houston, TX · +15 more sites

RecruitingPhase 1NCT06545331

Study of XB010 in Subjects With Solid Tumors

Sponsor: Exelixis

Austin, TX · Dallas, TX · Houston, TX · +13 more sites

RecruitingPhase 3NCT06617325

A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

Sponsor: UCB Biopharma SRL

Bellaire, TX · El Paso, TX · Fort Worth, TX · +60 more sites

RecruitingPhase 2 / Phase 3NCT06712316

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)

Sponsor: BioNTech SE

Houston, TX · +52 more sites

Listings come from ClinicalTrials.gov and are provided for information only. Always confirm eligibility with the study team and talk with your doctor before making decisions about your care.